Hemant Surgical Industries Limited has revised its disclosure regarding the Semi Knocked Down (SKD) Manufacturing Agreement with Sonomed Escalon, USA, to provide better clarity to investors. The agreement, initially disclosed on March 31, 2026, outlines the framework for manufacturing specific ophthalmic devices in India. The modifications were made at the request of Sonomed Escalon to enhance understanding of the arrangement.

The primary objective of the agreement is to undertake SKD manufacturing in India of two designated models of A-scan and pachymetry ophthalmic ultrasound devices. These products will be distributed exclusively within the Indian market. The scope of work for both parties has been defined according to SKD protocols and further localisation requirements.

Sonomed Escalon has agreed to supply components in SKD form at a preferential "Transfer Price." The pricing structure established under the agreement is exclusive of taxes, duties, customs, statutory levies, and shipping costs, unless otherwise agreed upon by the parties involved.

The regulatory filing confirms that there is no shareholding by Hemant Surgical Industries in Sonomed Escalon. Furthermore, the transaction does not fall under related party transactions, nor does it involve any special rights such as the appointment of directors or restrictions on capital structure. The promoter of Hemant Surgical Industries was previously an authorised distributor of Sonomed Escalon.

The revised disclosure was submitted to BSE Limited on June 09, 2026, in compliance with SEBI Circular SEBI/HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026. The filing was signed by Hanskumar Shamji Shah, Managing Director of Hemant Surgical Industries Limited.

Agreement Details

Hemant Surgical Industries Limited has acquired a 66.66% majority stake in Lifesenz Cancer Research Labs Private Limited for ₹19.98 Crores, effective June 01, 2026. This strategic acquisition makes Lifesenz a subsidiary of Hemant Surgical Industries , marking its entry into the precision oncology segment. The transaction aligns with the company's objective to expand beyond traditional healthcare distribution into advanced diagnostics and personalized medicine.

Lifesenz operates in precision oncology, utilizing patient-derived 3D cancer cell models for ex-vivo chemo-sensitivity analysis. This technology assists clinicians in selecting patient-specific treatments by evaluating effectiveness before therapy administration. The integration of Lifesenz's scientific capabilities with Hemant Surgical's established distribution network is expected to enhance its portfolio of differentiated healthcare solutions and strengthen relationships with hospitals and clinicians.

The Board of Directors evaluated the acquisition based on long-term strategic advantages rather than near-term profitability metrics. Management acknowledges that Lifesenz is currently in a growth and development phase, requiring investments in research and infrastructure, and will take time to break even. The acquisition was conducted on an arm's length basis to serve the best interests of the company.

Strategic Synergies and Future Outlook

The company plans to leverage its existing market reach to scale Lifesenz's operations. Key initiatives include strengthening clinical collaborations, expanding patient adoption, and increasing commercialization opportunities. Management believes that growing awareness of personalized cancer treatment will drive demand for these technologies in the coming years.

Hanskumar Shamji Shah, Managing Director of Hemant Surgical Industries Limited, stated that the acquisition reflects the company's commitment to the future of healthcare. He emphasized that combining Lifesenz's scientific expertise with Hemant Surgical's platform creates a foundation for long-term growth and improved patient care outcomes.